Moleculin Biotech ( (MBRX) ) has released its Q1 earnings. Here is a breakdown of the information Moleculin Biotech presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing treatments for hard-to-treat cancers and viral infections. Its lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.
In its first quarter 2025 financial results, Moleculin Biotech reported ongoing progress in its pivotal Phase 3 MIRACLE trial for Annamycin, with enrollment and dosing underway. The company received approval from the European Medicines Agency, allowing the trial to expand to nine additional countries in the EU.
Key financial metrics include a decrease in research and development expenses to $3.4 million from $4.3 million in the previous year, and a slight increase in general and administrative expenses to $2.5 million. The company reported a net loss of $6.4 million for the quarter, with cash and cash equivalents of $7.7 million as of March 31, 2025.
Moleculin’s strategic announcements include the expansion of its intellectual property portfolio with new U.S. patents and the presentation of pre-clinical data showing potential market expansion for Annamycin. The company is also advancing its pipeline with developments in its MB-107 trial and WP1066 program targeting brain tumors.
Looking ahead, Moleculin Biotech remains optimistic about its ongoing clinical trials and anticipates interim data readouts in the latter half of 2025. The company continues to focus on advancing its drug candidates towards potential regulatory approvals and expanding its market presence.